click enter text
full postview solid beat revenu ep
report financi result thursday open
beat revenu ep
guidanc first given decemb larg maintain
investor await result dian-tu trial lli solanezumab
roch gantenerumab come near-term seemingli high
likelihood failur could caus volatil downsid
howev work
one sourc option disappear today pegilodecakin io
space acquisit armo yet anoth
gener io agent bite dust
chang model rel modest pt target
bodi report full analysi
trade fundament data
upsid target
inform us/eu stock cover see
recent report global pharmaceut jan issu monthli
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
thursday market open
report result higher revenu ep vs consensu us
larg confirm prior non-gaap guidanc even recent acquir dermira
saw share price move approx day outperform drug group
overal impress thursday market open report financi result solid
larg quiet quarter disclosur confer call ph immuno-oncolog pipelin drug
pegilodecakin also fail lung cancer essenti dead press releas
morn view product high risk one offer asymmetr upsid option
potenti novel io agent paid product compani made small updat
financi guidanc first given assum may slight dilut ep
recent derm acquisit happen lli biggest area revenu concentr
diabet total top line sale perhap top mind investor compani alzheim
diseas platform span sever molecul asset class proxim news flow
like result smaller investigator-initi dian-tu trial solanezumab one
two activ drug arm rog gantenerumab ask odd success time
immin weigh odd time confirm result
continu least someth stock option tie read-out view result
highli like neg share may declin news yet alzheim diseas hope
trade live influenc addit data flow regulatori event across biopharma sector whether
compani unreason excit upsid option given
size commerci opportun think industri slowli work way toward find diseas
modifi drug term rest lli busi major new revel key product like
trulic continu track well investor natur continu watch trend evolv competitor
product like oral sema continu roll-out broadli topic direct impact alz
dz threw cold water concept novo talk recent high qualiti name
growth prospect look solid durabl question one valuat whether stock
fulli valu current rate peer perform inform see global
 jan issu monthli controversi report
revenu higher vs consensu
non-gaap ep higher vs consensu lower anticip tax rate
contribut boost ep
trulic higher consensu taltz higher vs
consensu
revenu rais vs
page
non-gaap ep maintain
reiter oper margin y/i expans
pipelin pegilodecakin appar dead armo acquisit
toplin posit olumi monotherapi treatment atop dermat come shortli breeze-
toplin posit day ago updat overt emphasi either posit neg
solanezumab alz dz includ dian-tu trial result soon
revenu decreas slightli ep increas derm acquisit appar
dilut ep model
revenu estim decreas ep estim increas
depend year oper margin meet guidanc
slightli consensu
ep compound-annual-growth-rate ep compound-annual-growth-rate increas well peer averag average
price target increas vs prior repres higher vs
new higher ep estim multipl peer group averag reflect
compani better compar lt ep growth rate market drift gener
tweak drug compani pt multipl
 cadenc financi result across quarter expect growth revenu pretti
consist throughout year mayb bit soft ciali loe also
recount often see sale lower prior year may happen relat ship
 drive stronger volum growth vs peer say relat new product cycl
compani enjoy expect volum strength seen replic across
 describ progress margin path om
expans say like improv later quarter
grew unusu rate moder even bring new product like derm asset
keep spend much flatter
page
 outlook reform focu legisl pathway regard yet see draft guidanc lot
swirl rumor includ expand part predict rebuff idea refer price
wait see
 dian-tu time odd success would concur odd failur high
sola trial say result hand yet avail quarter term odd
success note small trial say factor weigh favor success other wolf
comment one point appreci make higher risk trial view patient
one three particular genet mutat enrol could heterogen
term stage diseas sever enrol also opportun ask roch
view dian-tu today mute respons see link
 dian pessim trial shouldnt work given tailor-
made note small size trial heterogen outcom measur regardless
interest scientif question answer need hit overal composit efficaci endpoint
 outcom biib aducanumab influenc lli think broader ad opportun
say pivot particular way outcom continu pursu multipl option
 talk lack penetr trulic tirzepatid could impact whether
work ad see bbb penetr prerequisit class drug work
ad work
 lli view treatment whether make differ ad novo recent
suggest look forward see novo data say diabet drug benefici effect
cv end-organ damag mayb indirect benefit doubt direct
effect alz dz
 trial updat read yet take earli
reiter mid-sd us price declin diabet product like trulic
 high dose trulic make differ remain excit continu categori
growth expect rewind also high dose continu solidifi market leadership
believ baricitinib first approv oral jak atop dermat
page
 taltz need keep product go biggest opportun remain rheumatolog
confid continu grow still see much use anti-tnf therapi leav room upgrad
newer agent like
 olumi outlook given lower dose continu explor option get higher dose approv
realist odd success
 view particip atop dermat market lot competit
note well posit olumi made gener comment broader market potenti
recent derm acquisit bring asset excit view best class
 tyvyt plan outsid china view broader opportun
open consid ex-china opportun innov good partner note
product nrdl expect read out
 direct oncolog develop portfolio light failur pegilodecakin talk variou
asset still develop high probabl success occasion consid
higher risk program like pegilodecakin
claim addit neg studi includ lung expect initi
trial program
page
exhibit show compani report actual result vs estim consensu
exhibit result vs wr estim consensu
page
exhibit summar lli financi guidanc vs estim
exhibit guidanc vs wr estim old new
exhibit captur chang forecast
exhibit chang wr model
page
oldnewprior wolf estimatewolf bgross marginapprox bother meffect tax rateapprox oper incom approx guidancewr estimatesp revenu margin exp margin incom
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement incom loss cont op dilut share growth outstand
page
product revenu emgal galcanezumab anti-cgrp growth share tradjenta basaglar biosimilar share jardianc trulic women endocrinolog growth diabet alimta cyramza gastric lartruvo olaratumab verzenio abemaciclib erbitux total taltz ixekizumab olumi baricitinib jak total total earli stage factor- total
exhibit wr eli lilli balanc sheet cash flow statement
page
summari statement incom reconcil incom tax cash provid oper tax chang oper asset defer compens impair net in-process technolog net cash provid sale in-process product paid acq/loan cash provid use invest stock capit chang short term issuanc long term repay long-term cash provid use financ exchang rate cash increas decreas end balanc sheet cash equival short term properti plant goodwil current term non-curr paid-in comprehens treasuri stock sharehold liabil sharehold
